Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Thyroid Gland Hurthle Cell Carcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Thyroid Gland Carcinoma (344
)
Thyroid Gland Anaplastic Carcinoma (62
)
Thyroid Gland Medullary Carcinoma (58
)
Thyroid Gland Papillary Carcinoma (55
)
Thyroid Gland Follicular Carcinoma (25
)
Thyroid Gland Carcinoma (344
)
Thyroid Gland Anaplastic Carcinoma (62
)
Thyroid Gland Medullary Carcinoma (58
)
Thyroid Gland Papillary Carcinoma (55
)
Thyroid Gland Follicular Carcinoma (25
)
›
Associations
(12)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
denosumab
Sensitive: A2 - Guideline
denosumab
Sensitive
:
A2
denosumab
Sensitive: A2 - Guideline
denosumab
Sensitive
:
A2
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK3 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK3 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login